Licogliflozin is a dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor investigated for its potential in treating metabolic disorders such as obesity, type 2 diabetes mellitus, nonalcoholic steatohepatitis,… Read more
Licogliflozin is a dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor investigated for its potential in treating metabolic disorders such as obesity, type 2 diabetes mellitus, nonalcoholic steatohepatitis, and polycystic ovary syndrome. By blocking these transporters in the kidneys and intestines, this agent modulates glucose reabsorption and metabolism. To support the rigorous demands of pharmaceutical development and regulatory compliance, a range of high-quality related compounds is essential. These products, including precise analytical impurities, key metabolic degradation products, and stable isotope-labelled standards, are vital tools for researchers and laboratory professionals. They enable accurate impurity profiling, facilitate the development of robust analytical methods, and ensure stringent quality control throughout the lifecycle of pharmaceutical testing. By providing reliable reference materials, these compounds assist in maintaining the highest standards of safety and efficacy in the investigation of SGLT-inhibiting therapeutic agents.